The recently approved antiviral drug letermovir (Prevymis, Merck) significantly lowered the risk for clinically significant cytomegalovirus (CMV) infection compared with placebo in CMV-seropositive transplant recipients.
In the phase 3, placebo-controlled study, letermovir or placebo was administered orally or intravenously to 565 patients through week 14 after transplantation. The drug was given at a dosage of 480 mg per day, or 240 mg per day in patients who were taking